A Study of Pemetrexed in Children With Recurrent Cancer
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
To determine the response rate of pemetrexed given every 21 days for the treatment of
children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive
neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma,
medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.